"Bureaucratic" Zoon leaves CBER (Center for Biologics Evaluation and Research) to return to NIH (National Institutes of Health)
This article was originally published in Clinica
Executive Summary
Virologist Jesse Goodman has been named to replace Kathryn Zoon as director of US FDA's Center for Biologics Evaluation and Research (CBER). Dr Zoon, who announced her resignation on December 13, said she was driven away in part by the agency's recent decision to shift authority for therapeutic biologics to the FDA's drug centre.